Overview
- At a Capital Markets Day in London, the company set goals for five product launches, more than ten clinical programs and faster idea‑to‑clinic timelines by 2030.
- Zealand framed 2026 as catalyst‑rich, with petrelintide—an amylin‑targeting candidate partnered with Roche—scheduled for a Phase 2 readout in Q1 and Phase 3 obesity data for survodutide expected throughout the year.
- A new Boston research site will fuse the firm’s peptide expertise with AI‑driven discovery and advanced automation to accelerate development.
- Zealand announced a collaboration with OTR Therapeutics to pursue oral small‑molecule receptor agonists, with CNBC reporting $20 million upfront, a possible $10 million conditional payment, and up to $2.5 billion in potential milestones.
- The company recently paused dapiglutide to concentrate on more differentiated assets as competition from Novo Nordisk, Eli Lilly and others intensifies, and its shares are down about 29% in 2025 according to CNBC.